| Name | Title | Contact Details |
|---|
The IRONMAN Group is a leading organization in endurance sports, hosting over 230 events annually in more than 55 countries. Founded in 1978 with the first Hawaiian Iron Man Triathlon, the company has evolved from a single race into a global phenomenon, attracting over 600,000 participants each year. It operates as the largest mass-participation sports organizer worldwide, originally established as the World Triathlon Corporation in 1991. The IRONMAN Group offers a diverse portfolio of events, including the full-distance IRONMAN® Triathlon, the half-distance IRONMAN® 70.3®, and the Olympic-distance 5150™ Triathlon Series. They also organize running events like the Rock ‘n’ Roll® Running Series and the Standard Chartered Singapore Marathon™, as well as trail running and cycling events. The company promotes inclusivity, catering to elite athletes, amateur enthusiasts, families, and youth through programs like IRONKIDS® and Iron Girl®. Their mission is to inspire athletes of all levels with the ethos "ANYTHING IS POSSIBLE®."
Crossroads Automotive Group Inc. is a privately-held automotive dealership group based in Sanford, North Carolina, founded in 1996. The company specializes in new and used vehicle sales, service, and collision repair, operating multiple locations across North Carolina and Virginia. With a workforce of approximately 1,345 employees, Crossroads Automotive Group generates annual revenue of about $232 million. The company is committed to a customer-centric vehicle buying experience, guided by Christian principles. It emphasizes hiring skilled staff, maintaining large inventories, and providing compassionate service. Crossroads Automotive Group has expanded through acquisitions, including brands like Ford, Lincoln, INFINITI, Chrysler, Dodge, Jeep, and Ram. In addition to vehicle sales, the company offers automotive service, collision repair, maintenance, and financing options. It operates under various names, including Crossroads Ford and Crossroads Auto Group, and has established a strong presence in the automotive market.
Veteran Benefits Guide (VBG) is a benefit advisory company dedicated to assisting U.S. Armed Forces Veterans in maximizing their VA disability compensation ratings and benefits. Founded by Joshua Smith, a former Marine and VA rater, VBG provides pre-filing and post-filing consulting services. The company is headquartered in Las Vegas, Nevada, and has experienced significant growth since its inception in 2019. VBG employs a team of trained case managers, many of whom have backgrounds in the VA, to offer personalized guidance through the claims process. Their services include comprehensive reviews of military records, tailored claim strategies, and support for filing claims independently. VBG utilizes proprietary software to streamline the claims process and has a strong track record, boasting a 90% client success rate for favorable VA decisions and a perfect 5-star Google rating. The company emphasizes a Veteran-friendly approach, ensuring accuracy and efficiency in navigating the VAs Compensation & Pension process.
Verdegard offers a complete suite of innovative, integrated, and concierge-level services. Plan designs include PPO options, reference-based, level funded, and hybrid plans which provide unique transparency, patient advocacy, and cost containment options to maximize the benefits and savings.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.